Information Provided By:
Fly News Breaks for January 9, 2020
Jan 9, 2020 | 06:05 EDT
Piper Sandler analyst David Amsellem initiated coverage of BioDelivery Sciences with an Overweight rating and $9 price target. Visibility into "aggressive" volume and sales growth for Belbuca, BioDelivery's buccal film form of buprenorphine for chronic pain, is high, translating into "transformative" longer-term EBITDA growth, Amsellem tells investors in a research note. The analyst believes the product is "hitting its stride following some fits and starts early in its commercial life" and sees an attractive risk/reward at current share levels.
News For BDSI From the Last 2 Days
There are no results for your query BDSI